Mobocertinib is an orally active, acrylamide-armed, irreversible inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2, selectively suppressing exon-20-inserted variants in non-small cell lung cancer.
Usually ships within 24 hours.